Cullinan Oncology LLC
$ 15.06
2.17%
17 Apr - close price
- Market Cap 911,524,000 USD
- Current Price $ 15.06
- High / Low $ 15.20 / 14.77
- Stock P/E N/A
- Book Value 6.79
- EPS -3.36
- Next Earning Report 2026-05-14
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.28 %
- ROE -0.44 %
- 52 Week High 16.74
- 52 Week Low 5.68
About
Cullinan Management, Inc., a biopharmaceutical company, is focused on developing a line of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company is headquartered in Cambridge, Massachusetts.
Analyst Target Price
$31.35
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-05 | 2025-11-06 | 2025-08-07 | 2025-05-13 | 2025-03-12 | 2024-11-06 | 2024-08-08 | 2024-05-15 | 2024-03-14 | 2023-11-08 | 2023-08-10 | 2023-05-11 |
| Reported EPS | -0.77 | -0.77 | -1.19 | -0.74 | -0.73 | -0.69 | -0.75 | -0.86 | -0.54 | -0.91 | -0.82 | -1.42 |
| Estimated EPS | -0.8739 | -0.95 | -0.82 | -0.99 | -0.7423 | -0.81 | -0.73 | -0.99 | -0.96 | -0.92 | -0.97 | -0.98 |
| Surprise | 0.1039 | 0.18 | -0.37 | 0.25 | 0.0123 | 0.12 | -0.02 | 0.13 | 0.42 | 0.01 | 0.15 | -0.44 |
| Surprise Percentage | 11.8892% | 18.9474% | -45.122% | 25.2525% | 1.657% | 14.8148% | -2.7397% | 13.1313% | 43.75% | 1.087% | 15.4639% | -44.898% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-14 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.78 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: CGEM
2026-04-10 12:09:17
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) has received a consensus "Moderate Buy" recommendation from analysts, with an average one-year price target of $29.56, suggesting significant upside from its current share price of $15.21. The biopharmaceutical company recently reported better-than-expected earnings and is advancing multiple Phase I oncology programs. While institutional investors hold a large portion of the shares, insiders have been net sellers over the past 90 days.
2026-04-09 01:58:00
The article analyzes Cullinan Oncology Inc. (CGEM) using AI models, indicating strong sentiment across all time horizons. It provides institutional trading strategies including position trading (long), momentum breakout, and risk hedging (short), along with multi-timeframe signal analysis. The analysis identifies key support and resistance levels for CGEM, suggesting specific entry and exit points for various trading approaches.
2026-04-01 22:41:05
This page provides a comprehensive resource for Cullinan Oncology (CGEM) SEC filings, including 10-K, 10-Q, 8-K, and insider trading forms. It highlights key events such as clinical data updates for CLN-049 and CLN-978, financial results, and corporate actions. The platform also offers AI-powered summaries and sentiment analysis for these regulatory documents to assist investors in analyzing CGEM's progress and strategic direction.
2026-04-01 03:09:40
This page provides access to Cullinan Oncology Inc.'s (CGEM) SEC filings, including annual reports (10-K), quarterly earnings (10-Q), material event reports (8-K), and insider trading forms. It highlights recent filings detailing financial results, clinical trial updates for pipeline assets like CLN-049 and CLN-978, and corporate actions such as the discontinuation of certain programs. The platform also offers AI-powered summaries and impact analysis for easier interpretation of these regulatory documents.
2026-03-29 01:09:31
This article provides an AI-driven analysis of Cullinan Oncology Inc. (NASDAQ: CGEM), highlighting a mid-channel oscillation pattern and a strong risk-reward setup. It outlines specific institutional trading strategies including position trading, momentum breakout, and risk hedging, alongside multi-timeframe signal analysis. The report identifies positive near-term sentiment while noting a weak mid-term bias within a long-term strength context.
2026-03-24 19:39:04
Clear Street reiterated a Buy rating and a $777.00 price target for Cullinan Oncology (NASDAQ:CGEM) after Gilead Sciences' acquisition of Ouro Medicines. This acquisition validates Cullinan's velinotamig, which uses a similar BCMA x CD3 mechanism, and other clinical programs. The company has several data readouts expected in 2026 for its autoimmune and oncology programs, and analysts like Stifel and Guggenheim have also set Buy ratings with price targets of $28 and $30 respectively.
